Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.

The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene

Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789 · see citing works

Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6

Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B. F., Broxmeyer, H. E., & Manolagas, S. C. (1992) · Science · doi:10.1126/science.1621100 · Cited by 1,440 · see citing works

Primer on the metabolic bone diseases and disorders of mineral metabolism

Favus, M. J., & Slovik, D. (1994) · The Indian journal of medical research · doi:10.1136/ard.53.3.157-a · Cited by 1,117 · see citing works

Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells.

Udagawa, N., Takahashi, N., Akatsu, T., Tanaka, H., Sasaki, T., Nishihara, T., Koga, T., Martin, T. J., & Suda, T. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7260 · Cited by 1,048 · see citing works

Modulation of Osteoclast Differentiation

Suda, T., Takahashi, N., & Martin, T. J. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-66 · Cited by 996 · see citing works

OSTEOBLASTIC CELLS ARE INVOLVED IN OSTEOCLAST FORMATION

Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J., & Suda, T. (1988) · Endocrinology · doi:10.1210/endo-123-5-2600 · Cited by 934 · see citing works

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.

Tamura, T., Udagawa, N., Takahashi, N., Miyaura, C., Tanaka, S., Yamada, Y., Koishihara, Y., Ohsugi, Y., Kumaki, K., & Taga, T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11924 · Cited by 826 · see citing works

Disorders of Bone and Mineral Metabolism

Coe, F. L., Favus, M. J., & Davids, J. R. (1992) · Journal of Pediatric Orthopaedics · doi:10.1097/01241398-199211000-00022 · Cited by 734 · see citing works

Osteoclast-Like Cell Formation and its Regulation by Osteotropic Hormones in Mouse Bone Marrow Cultures*

Takahashi, N., Yamana, H., Yoshiki, S., Roodman, G. D., Mundy, G. R., Jones, S. J., BOYDE, A., & Suda, T. (1988) · Endocrinology · doi:10.1210/endo-122-4-1373 · Cited by 731 · see citing works

The Chromatographic Determination of Cystine and Cysteine Residues in Proteins as S-β-(4-Pyridylethyl)cysteine

Friedman, M., Krull, L. H., & Cavins, J. F. (1970) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)62930-8 · Cited by 518 · see citing works

The Bone Marrow-Derived Stromal Cell Lines MC3T3-G2/PA6 and ST2 Support Osteoclast-Like Cell Differentiation in Cocultures with Mouse Spleen Cells

Udagawa, N., Takahashi, N., Akatsu, T., Sasaki, T., Yamaguchi, A., KODAMA, H., Martin, T. J., & Suda, T. (1989) · Endocrinology · doi:10.1210/endo-125-4-1805 · Cited by 492 · see citing works

Congenital osteoclast deficiency in osteopetrotic (op/op) mice is cured by injections of macrophage colony-stimulating factor.

Kodama, H., Yamasaki, A., Nose, M., Niida, S., Ohgame, Y., Abe, M., Kumegawa, M., & Suda, T. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.1.269 · Cited by 353 · see citing works

Modulation of osteoclast differentiation by local factors

Suda, T., Udagawa, N., Nakamura, I., Miyaura, C., & Takahashi, N. (1995) · Bone · doi:10.1016/8756-3282(95)00185-g · Cited by 314 · see citing works

Generation of osteoclasts from isolated hematopoietic progenitor cells

Kurihara, N., Suda, T., Miura, Y., Nakauchi, H., Kodama, H., Hiura, K., Hakeda, Y., & Kumegawa, M. (1989) · Blood · doi:10.1182/blood.v74.4.1295.1295 · Cited by 202 · see citing works

Identity of a tumor cytotoxic factor from human fibroblasts and hepatocyte growth factor

Higashio, K., Shima, N., Goto, M., et al. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)91287-3 · Cited by 194 · see citing works

Delayed hematopoietic development in osteopetrotic (op/op) mice.

Begg, S. K., Radley, J., Pollard, J. W., Chisholm, O., Stanley, E. R., & Bertoncello, I. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.177.1.237 · Cited by 194 · see citing works

Spleen Cells Transmit Osteopetrosis in Mice

Walker, D. G. (1975) · Science · doi:10.1126/science.1198094 · Cited by 129 · see citing works

Interleukin 4, interferon-gamma, and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages

Lacey, D. L., Erdmann, J. M., Teitelbaum, S. L., Tan, H., Ohara, J., & Shioi, A. (1995) · Endocrinology · doi:10.1210/endo.136.6.7750457 · Cited by 87 · see citing works

The primary structure and structural characteristics of Achromobacter lyticus protease I, a lysine-specific serine protease

Tsunasawa, S., Masaki, T., Hirose, M., et al. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)84926-8 · Cited by 85 · see citing works

Disorders of Bone and Mineral Metabolism

Wallis, L. A. (1993) · JAMA · doi:10.1001/jama.1993.03500100113044 · Cited by 64 · see citing works

Cellular and Molecular Mechanisms in the Regulation and Function of Osteoclasts

Chambers, T. J., & Hall, T. J. (1991) · Vitamins and hormones · doi:10.1016/s0083-6729(08)60682-2 · Cited by 57 · see citing works

Interferons-α and -γ Inhibit Interleukin-1β-Stimulated Osteoclast-Like Cell Formation in Long-Term Human Marrow Cultures

Kurihara, N., & Roodman, G. D. (1990) · Journal of Interferon Research · doi:10.1089/jir.1990.10.541 · Cited by 36 · see citing works

Mouse Osteoblastic Cells (MC3T3-E1) at Different Stages of Differentiation Have Opposite Effects on Osteoclastic Cell Formation

Hiura, K., Sumitani, K., Kawata, T., HIGASHINO, K., Okawa, M., Sato, T., Hakeda, Y., & Kumegawa, M. (1991) · Endocrinology · doi:10.1210/endo-128-3-1630 · Cited by 31 · see citing works

Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems

Takayanagi, H. (2007) · Nature Reviews Immunology · doi:10.1038/nri2062 · Cited by 1,878 · see citing works

Minireview: The OPG/RANKL/RANK System

Khosla, S. (2001) · Endocrinology · doi:10.1210/endo.142.12.8536 · Cited by 1,515 · see citing works

Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis<i>in Vitro</i>¹

Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201 · see citing works

Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease

Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824 · see citing works

Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1

Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794 · see citing works

Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.

Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775 · see citing works

RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis

Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9788 · Cited by 746 · see citing works

OSTEOIMMUNOLOGY: Interplay Between the Immune System and Bone Metabolism

Walsh, M. C., Kim, N., Kadono, Y., Rho, J., Lee, S. Y., Lorenzo, J., & Choi, Y. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090646 · Cited by 724 · see citing works

The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689 · see citing works

Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond

Walsh, M. C., & Choi, Y. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00511 · Cited by 599 · see citing works

Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology

Hofbauer, L. C., & Heufelder, A. E. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100226 · Cited by 586 · see citing works

Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.

Pearse, R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein, J., & Choi, Y. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201394498 · Cited by 518 · see citing works

Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption

Sims, N. A., & Gooi, J. H. (2008) · Seminars in Cell &amp; Developmental Biology · doi:10.1016/j.semcdb.2008.07.016 · Cited by 513 · see citing works

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.

Body, J.-J., Facon, T., Coleman, R. E., Lipton, A., Geurs, F., Fan, M., Holloway, D., Peterson, M. C., & Bekker, P. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1933 · Cited by 490 · see citing works

The effect of a single dose of osteoprotegerin in postmenopausal women.

Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484 · see citing works

Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.

Lee, S.-K., & Lorenzo, J. A. (1999) · Endocrinology · doi:10.1210/endo.140.8.6887 · Cited by 464 · see citing works

Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.

Ma, Y. L., Cain, R. L., Halladay, D. L., Yang, X., Zeng, Q., Miles, R. R., Chandrasekhar, S., Martin, T. J., & Onyia, J. E. (2001) · Endocrinology · doi:10.1210/endo.142.9.8356 · Cited by 428 · see citing works

RANK/RANKL: Regulators of Immune Responses and Bone Physiology

Leibbrandt, A., & Penninger, J. M. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1443.016 · Cited by 420 · see citing works

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

Body, J.-J., Greipp, P., Coleman, R. E., Facon, T., Geurs, F., Fermand, J.-P., Harousseau, J.-L., Lipton, A., Mariette, X., Williams, C. D., et al. (2003) · Cancer · doi:10.1002/cncr.11138 · Cited by 383 · see citing works

Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.

Yano, K., Tsuda, E., Washida, N., Kobayashi, F., Goto, M., Harada, A., Ikeda, K., Higashio, K., & Yamada, Y. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.4.518 · Cited by 363 · see citing works

The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts.

Bord, S., Ireland, D. C., Beavan, S. R., & Compston, J. E. (2003) · Bone · doi:10.1016/s8756-3282(02)00953-5 · Cited by 333 · see citing works

OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40.

Yun, T. J., Chaudhary, P. M., Shu, G. L., Frazer, J. K., Ewings, M. K., Schwartz, S. M., Pascual, V., Hood, L. E., & Clark3, E. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.11.6113 · Cited by 307 · see citing works

Transforming Growth Factor-β Stimulates the Production of Osteoprotegerin/Osteoclastogenesis Inhibitory Factor by Bone Marrow Stromal Cells

Takai, H., Kanematsu, M., Yano, K., Tsuda, E., Higashio, K., Ikeda, K., Watanabe, K., & Yamada, Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.42.27091 · Cited by 299 · see citing works

Receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.

Grimaud, E., Soubigou, L., Couillaud, S., Coipeau, P., Moreau, A., Passuti, N., Gouin, F., Redini, F., & Heymann, D. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63560-2 · Cited by 282 · see citing works

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.

KOSTENUIK, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.06.005 · Cited by 281 · see citing works

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.

Standal, T., Seidel, C., Hjertner, Ø., Plesner, T., Sanderson, R. D., Waage, A., Borset, M., & Sundan, A. (2002) · Blood · doi:10.1182/blood-2002-04-1190 · Cited by 244 · see citing works

IL-1 plays an important role in the bone metabolism under physiological conditions

Lee, Y.-M., Fujikado, N., Manaka, H., Yasuda, H., & Iwakura, Y. (2010) · International Immunology · doi:10.1093/intimm/dxq431 · Cited by 226 · see citing works

Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor κB Ligand: Clinical Utility in Metabolic Bone Disease Assessment

Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215 · see citing works

RANKL/OPG; Critical role in bone physiology

Martin, T. J., & Sims, N. A. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9308-6 · Cited by 213 · see citing works

Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.

Rogers, A., Saleh, G., Hannon, R. A., Greenfield, D., & Eastell, R. (2002) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2002-020396 · Cited by 200 · see citing works

Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory Factor

Yamaguchi, K., Kinosaki, M., Goto, M., Kobayashi, F., Tsuda, E., Morinaga, T., & Higashio, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.9.5117 · Cited by 200 · see citing works

Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function.

Yun, T. J., Tallquist, M. D., Aicher, A., Rafferty, K. L., Marshall, A. J., Moon, J. J., Ewings, M. K., Mohaupt, M., Herring, S. W., & Clark, E. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.3.1482 · Cited by 195 · see citing works

Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids.

Vidal, N., Brandstrom, H., Jonsson, K., & Ohlsson, C. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1590191 · Cited by 185 · see citing works

Mechanism of osteoclast mediated bone resorption—rationale for the design of new therapeutics

VAANANEN, K. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.018 · Cited by 176 · see citing works

Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.

Humphrey, E. L., Williams, J. H. H., Davie, M. W. J., & Marshall, M. J. (2006) · Bone · doi:10.1016/j.bone.2005.10.004 · Cited by 139 · see citing works

RANK (receptor activator of nuclear factor-κB) and RANKL expression in multiple myeloma.

Roux, S., Meignin, V., Quillard, J., Meduri, G., Guiochon‐Mantel, A., Fermand, J., Milgrom, E., & Mariette, X. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03417.x · Cited by 125 · see citing works

Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast.

Akatsu, T., Murakami, T., Nishikawa, M., Ono, K., Shinomiya, N., Tsuda, E., Mochizuki, S.-I., Yamaguchi, K., Kinosaki, M., Higashio, K., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9294 · Cited by 123 · see citing works

Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation.

Nagai, M., & Sato, N. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0524 · Cited by 111 · see citing works

Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts.

Hakeda, Y., Kobayashi, Y., Yamaguchi, K., Yasuda, H., Tsuda, E., Higashio, K., Miyata, T., & Kumegawa, M. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9523 · Cited by 107 · see citing works

Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro.

Chikatsu, N., Takeuchi, Y., Tamura, Y., Fukumoto, S., Yano, K., Tsuda, E., Ogata, E., & Fujita, T. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.2008 · Cited by 95 · see citing works

The origins and formation of bone-resorbing osteoclasts

Elson, A., Anuj, A., Barnea-Zohar, M., & Reuven, N. (2022) · Bone · doi:10.1016/j.bone.2022.116538 · Cited by 95 · see citing works

Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.

Itoh, K., Udagawa, N., Matsuzaki, K., Takami, M., Amano, H., Shinki, T., Ueno, Y., Takahashi, N., & Suda, T. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.9.1766 · Cited by 90 · see citing works

Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy.

Akatsu, T., Murakami, T., Ono, K., Nishikawa, M., Tsuda, E., Mochizuki, S.-I., Fujise, N., Higashio, K., Motoyoshi, K., Yamamoto, M., et al. (1998) · Bone · doi:10.1016/s8756-3282(98)00141-0 · Cited by 87 · see citing works

Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios.

J�rgensen, H. L., Kusk, P., Madsen, B., Fenger, M., & Lauritzen, J. B. (2004) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-003-0461-3 · Cited by 85 · see citing works

Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor.

Tomoyasu, A., Goto, M., Fujise, N., Mochizuki, S.-I., Yasuda, H., Morinaga, T., Tsuda, E., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8443 · Cited by 83 · see citing works

Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population.

Gannagé‐Yared, M., Fares, F., Semaan, M., Khalife, S., & Jambart, S. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02522.x · Cited by 76 · see citing works

Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells.

Nakagawa, N., Yasuda, H., Yano, K., Mochizuki, S.-I., Kobayashi, N., Fujimoto, H., Shima, N., Morinaga, T., Chikazu, D., Kawaguchi, H., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1601 · Cited by 64 · see citing works

Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL

BORD, S., FRITH, E., IRELAND, D., SCOTT, M., CRAIG, J., & COMPSTON, J. (2005) · Bone · doi:10.1016/j.bone.2004.12.006 · Cited by 63 · see citing works

Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status.

Fahrleitner-Pammer, A., Dobnig, H., Piswanger-Soelkner, C., Bonelli, C., Dimai, H.-P., Leb, G., & Obermayer-Pietsch, B. (2003) · Wiener Klinische Wochenschrift · doi:10.1007/bf03040334 · Cited by 62 · see citing works

Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women.

Oh, E. S., Rhee, E.-J., Oh, K. W., Lee, W. Y., Baek, K. H., Yoon, K. H., Kang, M. I., Yun, E. J., Park, C. Y., Choi, M. G., et al. (2005) · Metabolism · doi:10.1016/j.metabol.2004.08.005 · Cited by 61 · see citing works

Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria.

O'Brien, E. A., Williams, J. H. H., & Marshall, M. J. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3129 · Cited by 61 · see citing works

Osteoclast formation and bone resorption are inhibited by megakaryocytes

Beeton, C. A., Bord, S., Ireland, D., & Compston, J. E. (2006) · Bone · doi:10.1016/j.bone.2006.06.004 · Cited by 61 · see citing works

Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen

Bord, S., Frith, E., Ireland, D. C., Scott, M. A., Craig, J. I. O., & Compston, J. E. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05024.x · Cited by 56 · see citing works

Vector-averaged gravity regulates gene expression of receptor activator of NF-κB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway

Kanematsu, M., Yoshimura, K., Takaoki, M., & Sato, A. (2002) · Bone · doi:10.1016/s8756-3282(02)00680-4 · Cited by 31 · see citing works

Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats.

Mochizuki, S.-I., Fujise, N., Higashio, K., & Tsuda, E. (2002) · Journal of Bone and Mineral Metabolism · doi:10.1007/s774-002-8441-x · Cited by 24 · see citing works

Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts.

Doran, P. M., Turner, R. T., Chen, D., Facteau, S. M., Ludvigson, J. M., Khosla, S., Riggs, B. L., & Russell, S. J. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2004.01.006 · Cited by 22 · see citing works

Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover

Uemura, H., Yasui, T., Umino, Y., Niki, H., Takikawa, M., Saito, S., Furumoto, H., & Irahara, M. (2003) · Bone · doi:10.1016/j.bone.2003.08.001 · Cited by 7 · see citing works

ФОРМИРОВAНИЕ ГОТОВНОСТИ БУДУЩИХ ПЕДAГОГОВ К ОРГAНИЗAЦИИ РAБОТЫ ПО РAЗВИТИЮ ВAЛЕОЛОГИЧЕСКОЙ КУЛЬТУРЫ ШКОЛЬНИКОВ

БАЗАРБАЕВА, Ә. А., Майгельдиева, Ш. М., & ЖҮНДІБАЕВА, Т. Н. (2023) · Pedagogy and Psychology · doi:10.51889/2077-6861.2023.1.30.016

Коммуникaтивно- прaгмaтический aнaлиз дипломaтических бумaг (нa основе вербaльных нот)

Кaмирдиновa, Н., & Кaлиевa, Ш. С. (2018) · DOAJ (DOAJ: Directory of Open Access Journals)

Susquehanna Chorale Spring Concert "Roots and Wings"

Hawkins, D. (2017)

A GEOMETRIC MEAN IN THE FURUTA INEQUALITY

Fujii, M., & Nakamoto, R. (2002) · Scientiae mathematicae Japonicae · Cited by 15 · see citing works

Darstellung perhalogenierter Dimethyldisulfane durch photochemische Reaktion von CSF2 und CSFCI mit Sulfenylbromiden bzw. ‐chloriden

HAAS, A., & Klug, W. (1968) · Chemische Berichte · doi:10.1002/cber.19681010803 · Cited by 22 · see citing works